Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.

Rizvi NA, Rusch V, Pao W, Chaft JE, Ladanyi M, Miller VA, Krug LM, Azzoli CG, Bains M, Downey R, Flores R, Park B, Singh B, Zakowski M, Heelan RT, Shen R, Kris MG
Clin Cancer Res. 2011 17 (10): 3500-6

PMID: 21558399 · PMCID: PMC3261615 · DOI:10.1158/1078-0432.CCR-10-2102

MeSH Terms (22)

Adult Aged Aged, 80 and over Carcinoma, Non-Small-Cell Lung Catalytic Domain Drug Resistance, Neoplasm ErbB Receptors Female Gefitinib Genes, erbB-1 Humans Lung Neoplasms Male Middle Aged Mutation Prognosis Protein Binding Protein Kinase Inhibitors Quinazolines Survival Analysis Treatment Outcome Tyrosine

Connections (1)

This publication is referenced by other Labnodes entities: